Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses

Blood

Volumn 101, Issue 9, 2003, Pages 3628-3634

  Li, Henry Y ^b   Appelbaum, Frederick R ^b   Willman, Cheryl L ^b   Zager, Richard A ^b   Banker, Deborah E ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ZARAGOZIC ACID A; ANTINEOPLASTIC AGENT; CHOLESTEROL; CYTARABINE; DAUNORUBICIN; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; LOW DENSITY LIPOPROTEIN; MEMBRANE LIPID; MEVINOLIN; RADIOSENSITIZING AGENT; TRICARBOXYLIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL KILLING; CELL SURVIVAL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG SENSITIZATION; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; ACUTE DISEASE; BIOSYNTHESIS; CELL CULTURE; CELL STRAIN HL 60; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; RADIATION EXPOSURE;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BONE MARROW CELLS; CHOLESTEROL; CYTARABINE; DAUNORUBICIN; DRUG SYNERGISM; HL-60 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA, MYELOID; LIPOPROTEINS, LDL; LOVASTATIN; MEMBRANE LIPIDS; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RADIATION-SENSITIZING AGENTS; TRICARBOXYLIC ACIDS; TUMOR CELLS, CULTURED;

EID: 0038121035     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2283     Document Type: Article

References (39)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
2. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med. 1998;104:2S-5S.
3. Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B. Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am J Pathol. 1998;153:1923-1935.
4. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methyl-glutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84:2689-2698.
5. Maksumova L, Ohnishi K, Muratkhodjaev F, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia. 2000;14:1444-1450.
6. May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int J Cancer. 1988;42:728-733.
7. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. J Clin Invest. 1985;76:1748-1754.
8. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and phenylacetate against human glioma cells. J Neurochem. 1996;66:710-716.
9. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001;7:3158-167.
10. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol. 1998;12:717-723.
11. Clutterbuck RD, Millar BC, Powles RL, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998;102:522-527.
12. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483-491.
13. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;93:1308-1318.
14. Stirewalt DL, Appelbaum FR, Willman CL, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003;27:135-147.
15. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079.
16. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999;13:502-513.
17. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol. 1998;18:85-92.
18. Mangues R, Corral T, Kohl NE, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 1998;58:1253-1259.
19. Beaupre DM, Talpaz M, Marini FC III, et al. Autocrine interleukin-1-β production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999;59:2971-2980.
20. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia. 2001;15:1398-1407.
21. Sinensky M, Beck LA, Leonard S, Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem. 1990;265:19937-19941.
22. Zager RA, Burkhart KM, Johnson AC, Sacks BM. Increased proximal tubular cholesterol content: implications for cell injury and "acquired cytoresistance." Kidney Int. 1999;56:1788-1797.
23. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
24. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977;270:347-349.
25. Skubitz KM, Zhen Y, August JT. A human granulocyte-specific antigen characterized by use of monoclonal antibodies. Blood. 1983;61:19-26.
26. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood. 1980;56:265-273.
27. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89:243-255.
28. Zager RA, Kalhorn TF. Changes in free and esterified cholesterol: hallmarks of acute renal tubular injury and acquired cytoresistance. Am J Pathol. 2000;157:1007-1016.
29. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors: a new therapeutic alternative. Drugs. 1988;36(suppl 3):72-82.
30. Zager RA. Plasma membrane cholesterol: a critical determinant of cellular energetics and tubular resistance to attack. Kidney Int. 2000;58:193-205.
31. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A. 1993;90:80-84.
32. Amin D, Rutledge RZ, Needle SN, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther. 1997;281:746-752.
33. Holstein SA, Hohl RJ. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res. 2001;25:651-660.
34. Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med. 2001;49:319-324.
35. Maccarrone M, Bellincampi L, Melino G, Finazzi-Agro A. Cholesterol, but not its esters, triggers programmed cell death in human erythroleukemia K562 cells. Eur J Biochem. 1998;253:107-113.
36. Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 1997;57:3498-3505.
37. Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood. 1991;77:1064-1070.
38. Hiyoshi H, Yanagimachi M, Ito M, et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. J Lipid Res. 2000;41:1136-1144.
39. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol. 2000;131:63-70.